Injectable poly- l -lactic acid for human immunodeficiency virus-associated facial lipoatrophy: Cumulative year 2 interim analysis of an open-label study (FACES)

Dermatologic Surgery

Volumn 38, Issue 7 PART 2, 2012, Pages 1193-1205

  Bassichis, Benjamin ^a   Blick, Gary ^b   Conant, Marcus ^c   Condoluci, David ^d   Echavez, Michael ^e,f   Eviatar, Joseph ^g   Gold, Michael H ^h   Hamilton, Tiffani ⁱ   Hanke, C William ^j   Humble, Gail ^k   Lamarca, Anthony ^l   Daro Kaftan, Elizabeth ^m   Mest, Douglas ^k   Pierone, Gerald ⁿ  

^a Advanced Facial Plastic Surgery Center   (United States)

^b Circle Medical ^*  (United States)

^c Conant Medical Group ^*  (United States)

^d Garden State Infectious Diseases Associates   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Facial Plastic Surgery   (United States)

^g NEW YORK MEDICAL COLLEGE   (United States)

^h GOLD SKIN CARE CENTER   (United States)

ⁱ Atlanta Dermatology   (United States)

^j Laser and Skin Surgery Center of Indiana   (United States)

^k Blue Pacific Aesthetic Medical Group   (United States)

^l Therafirst Medical Center   (United States)

^m Peloton Advantage LLC   (United States)

ⁿ Facial Rejuvenation   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

POLYLACTIC ACID;

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL EFFECTIVENESS; CONTUSION; DERMATITIS; DISEASE SEVERITY; ECCHYMOSIS; FACE MALFORMATION; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INJECTION PAIN; INJECTION SITE; INJECTION SITE BLEEDING; INJECTION SITE DISCOLORATION; INJECTION SITE NODULE; INJECTION SITE REACTION; INJECTION SITE SWELLING; KELOID; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAPULE; PATIENT SAFETY; PATIENT SATISFACTION; PRESYNCOPE; PRIORITY JOURNAL; SCAR;

ADIPOSE TISSUE; ADULT; AGED; ATROPHY; COSMETIC TECHNIQUES; FEMALE; HIV INFECTIONS; HUMANS; INJECTIONS; LACTIC ACID; MALE; MIDDLE AGED; PATIENT SATISFACTION; POLYMERS;

EID: 84863714400     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2012.02474.x     Document Type: Article

References (43)

1. Guaraldi G, Murri R, Orlando G, Squillace N, et al. Lipodystrophy and quality of life of HIV-infected persons. AIDS Rev 2008; 10: 152-61.
2. James J, Carruthers A, Carruthers J,. HIV-associated facial lipoatrophy. Dermatol Surg 2002; 28: 979-86.
3. Burgess CM, Quiroga RM,. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005; 52: 233-9.
4. Collins E, Wagner C, Walmsley S,. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read 2000; 10: 546-50.
5. Power R, Tate HL, McGill SM, Taylor C,. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect 2003; 79: 137-41.
6. Rajagopalan R, Laitinen D, Dietz B,. Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy. AIDS Care 2008; 20: 1197-201.
7. Duran S, Saves M, Spire B, Cailleton V, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15: 2441-4.
8. Sculptra. Sculptra [package insert]. Bridgewater, NJ: Dermik Laboratories, a business of sanofi-aventis U.S. LLC; 2009.
9. Sculptra Aesthetic. Sculptra Aesthetic [package insert]. Bridgewater, NJ: Dermik Laboratories, a business of sanofi-aventis U.S. LLC; 2009.
10. Vleggaar D,. Facial volumetric correction with injectable poly-L-lactic acid. Dermatol Surg 2005; 31 (11 Pt 2): 1511-8.
11. Lacombe V,. Sculptra: a stimulatory filler. Facial Plast Surg 2009; 25: 95-9.
12. Gogolewski S, Jovanovic M, Perren SM, Dillon JG, et al. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res 1993; 27: 1135-48.
13. Salles AG, Lotierzo PH, Gimenez R, Camargo CP, et al. Evaluation of the poly-L-lactic acid implant for treatment of the nasolabial fold: 3-year follow-up evaluation. Aesthetic Plast Surg 2008; 32: 753-6.
14. Vleggaar D,. Soft-tissue augmentation and the role of poly-L-lactic acid. Plast Reconstr Surg 2006; 118 (3 Suppl): 46S-54S.
15. Moyle GJ, Lysakova L, Brown S, Sibtain N, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004; 5: 82-7.
16. Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003; 17: 2471-7.
17. Cattelan AM, Bauer U, Trevenzoli M, Sasset L, et al. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy. Arch Dermatol 2006; 142: 329-34.
18. Mest DR, Humble G,. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg 2006; 32: 1336-45.
19. Moyle GJ, Brown S, Lysakova L, Barton SE,. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 2006; 7: 181-5.
20. Levy RM, Redbord KP, Hanke CW,. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study. J Am Acad Dermatol 2008; 59: 923-33.
21. Hanke CW, Redbord KP,. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. J Drugs Dermatol 2007; 6: 123-8.
22. Mest DR, Humble GM,. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study. Dermatol Surg 2009; 35 (Suppl 1): 350-9.
23. Rossner F, Rossner M, Hartmann V, Erdmann R, et al. Decrease of reported adverse events to injectable polylactic acid after recommending an increased dilution: 8-year results from the Injectable Filler Safety study. J Cosmet Dermatol 2009; 8: 14-8.
24. Odunze M, Cohn A, Few JW,. Restylane and people of color. Plast Reconstr Surg 2007; 120: 2011-6.
25. Fitzpatrick TB,. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124: 869-71.
26. Wu AW, Revicki DA, Jacobson D, Malitz FE,. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997; 6: 481-93.
27. Lowe NJ, Maxwell CA, Lowe P, Shah A, et al. Injectable poly- l -lactic acid: 3 years of aesthetic experience. Dermatol Surg 2009; 35 (Suppl 1): 344-9.
28. Narins RS, Baumann L, Brandt FS, Fagien S, et al. A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol 2010; 62: 448-62.
29. Mest DR, Humble GM,. Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid. Aesthetic Plast Surg 2009; 33: 654-6.
30. Kates LC, Fitzgerald R,. Poly-L-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review. Aesthet Surg J 2008; 28: 397-403.
31. Butterwick K, Lowe NJ,. Injectable poly-L-lactic acid for cosmetic enhancement: learning from the European experience. J Am Acad Dermatol 2009; 61: 281-93.
32. Lam SM, Azizzadeh B, Graivier M,. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring. Plast Reconstr Surg 2006; 118: 55S-63S.
33. Narins RS,. Minimizing adverse events associated with poly-L-lactic acid injection. Dermatol Surg 2008; 34 (Suppl 1): S100-4.
34. Guaraldi G, Orlando G, De Fazio D, De Lorenzi I, et al. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. Antivir Ther 2005; 10: 753-9.
35. Brandt FS, Cazzaniga A, Baumann L, Fagien S, et al. Investigator global evaluations of efficacy of injectable poly-L-lactic acid versus human collagen in the correction of nasolabial fold wrinkles. Aesthet Surg J 2011; 31: 521-8.
36. Skeie L, Bugge H, Negaard A, Bergersen BM,. Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study. HIV Med 2010; 11: 170-7.
37. Bugge H, Negaard A, Skeie L, Bergersen B,. Hyaluronic acid treatment of facial fat atrophy in HIV-positive patients. HIV Med 2007; 8: 475-82.
38. Jones DH, Carruthers A, Orentreich D, Brody HJ, et al. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial. Dermatol Surg 2004; 30: 1279-86.
39. Carruthers A, Carruthers J,. Evaluation of injectable calcium hydroxylapatite for the treatment of facial lipoatrophy associated with human immunodeficiency virus. Dermatol Surg 2008; 34: 1486-99.
40. Silvers SL, Eviatar JA, Echavez MI, Pappas AL,. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg 2006; 118 (3 Suppl): 34S-45S.
41. Cohen SR, Berner CF, Busso M, Gleason MC, et al. ArteFill: a long-lasting injectable wrinkle filler material-summary of the U.S. Food and Drug Administration trials and a progress report on 4- to 5-year outcomes. Plast Reconstr Surg 2006; 118 (3 Suppl): 64S-76S.
42. Carey D, Liew S, Emery S,. Restorative interventions for HIV facial lipoatrophy. AIDS Rev 2008; 10: 116-24.
43. Sturm LP, Cooter RD, Mutimer KL, Graham JC, et al. A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy. AIDS Patient Care and STDs 2009; 23: 699-714.